M E Erro1,2, M V Zelaya3,4, M Mendioroz5,6, R Larumbe5,6, S Ortega-Cubero7, J L Lanciego8,9, A Lladó10, T Cabada6,11, T Tuñón3,4, F García-Bragado3,4, M R Luquin12, P Pastor13, I Ferrer9,14. 1. Neurology Department, Complejo Hospitalario de Navarra, C/Irunlarrea 3, 31008, Pamplona, Navarra, Spain. elena.erro.aguirre@cfnavarra.es. 2. Neuroepigenetics Laboratory-Navarrabiomed, Complejo Hospitalario de Navarra, Universidad Pública de Navarra (UPNA), IdiSNA (Navarra Institute for Health Research), Pamplona, Spain. elena.erro.aguirre@cfnavarra.es. 3. Pathology Department, Complejo Hospitalario de Navarra, Pamplona, Spain. 4. Brain Bank, Navarrabiomed, IdiSNA (Navarra Institute for Health Research), Pamplona, Spain. 5. Neurology Department, Complejo Hospitalario de Navarra, C/Irunlarrea 3, 31008, Pamplona, Navarra, Spain. 6. Neuroepigenetics Laboratory-Navarrabiomed, Complejo Hospitalario de Navarra, Universidad Pública de Navarra (UPNA), IdiSNA (Navarra Institute for Health Research), Pamplona, Spain. 7. Neurosurgery and Neurology Department, Hospital Universitario de Burgos, Burgos, Spain. 8. Neurosciences Department, Center for Applied Medical Research (CIMA), IdiSNA (Navarra Institute for Health Research), Pamplona, Spain. 9. Biomedical Network Research Centre of Neurodegenerative Diseases (CIBERNED), Madrid, Spain. 10. Alzheimer's Disease and Other Cognitive Disorders Unit. Neurology Department, IDIBAPS. Hospital Clínic, Barcelona, Spain. 11. Neuroradiology Department, Complejo Hospitalario de Navarra, Pamplona, Spain. 12. Neurology Department, Clínica Universidad de Navarra, IdiSNA (Navarra Institute for Health Research), Pamplona, Spain. 13. Movement Disorders Unit, Neurology Department, Hospital Universitari Mutua de Terrassa, University of Barcelona School of Medicine and Fundació per la Recerca Biomèdica i Social Mútua Terrassa, Terrassa, Barcelona, Spain. 14. University of Barcelona, Bellvitge University Hospital-IDIBELL, Hospitalet de Llobregat, Hospitalet de Llobregat, Spain.
Abstract
OBJECTIVE: To describe the clinical, biochemical, and neuropathological findings of an autosomal dominant globular glial tauopathy caused by the P301T mutation at the MAPT gene. METHODS: Five patients from two unrelated pedigrees underwent clinical evaluation. Genetic analysis, brain pathological examination, and biochemical analysis of tau were performed. RESULTS: The patients studied were 3 men and 2 women with a mean age at onset of 52.2 years and mean disease duration of 5.2 years. Three patients presented a corticobasal syndrome, one patient an asymmetric pyramidal syndrome compatible with primary lateral sclerosis, and one patient a frontotemporal dementia. In both pedigrees (4 patients) Sanger sequencing showed the p.P301T mutation in exon 10 of the MAPT gene. Neuropathological findings consisted of atrophy of frontal and temporal lobes with marked spongiosis and astrogliosis, and abundant phosphorylated tau protein deposits in the frontal and temporal cortex, limbic area, basal ganglia, and brain stem. The most striking finding was the presence of oligodendroglial 4R phospho-tau globular positive inclusions in the white matter and cortex. Globose-type neurofibrillary neuronal tangles, and in particular astrocytic globular inclusions and coarse tufts, were present in the grey matter. Biochemical analysis of sarkosyl-insoluble fractions revealed two tau bands of 64 and 68 kDa and case-dependent bands of lower molecular weight. CONCLUSION: This is the first pathological and biochemical study of the MAPT p.P301T mutation showing variable clinical manifestation and neuropathological phenotype of globular glial tauopathy not only among different families but also within families.
OBJECTIVE: To describe the clinical, biochemical, and neuropathological findings of an autosomal dominant globular glial tauopathy caused by the P301T mutation at the MAPT gene. METHODS: Five patients from two unrelated pedigrees underwent clinical evaluation. Genetic analysis, brain pathological examination, and biochemical analysis of tau were performed. RESULTS: The patients studied were 3 men and 2 women with a mean age at onset of 52.2 years and mean disease duration of 5.2 years. Three patients presented a corticobasal syndrome, one patient an asymmetric pyramidal syndrome compatible with primary lateral sclerosis, and one patient a frontotemporal dementia. In both pedigrees (4 patients) Sanger sequencing showed the p.P301T mutation in exon 10 of the MAPT gene. Neuropathological findings consisted of atrophy of frontal and temporal lobes with marked spongiosis and astrogliosis, and abundant phosphorylated tau protein deposits in the frontal and temporal cortex, limbic area, basal ganglia, and brain stem. The most striking finding was the presence of oligodendroglial 4R phospho-tau globular positive inclusions in the white matter and cortex. Globose-type neurofibrillary neuronal tangles, and in particular astrocytic globular inclusions and coarse tufts, were present in the grey matter. Biochemical analysis of sarkosyl-insoluble fractions revealed two tau bands of 64 and 68 kDa and case-dependent bands of lower molecular weight. CONCLUSION: This is the first pathological and biochemical study of the MAPTp.P301T mutation showing variable clinical manifestation and neuropathological phenotype of globular glial tauopathy not only among different families but also within families.
Entities:
Keywords:
Corticobasal degeneration; Frontotemporal dementia; Genetic linkage; Globular glial tauopathy; Progressive supranuclear palsy; Protein tau
Authors: Pawel Tacik; Michael DeTure; Wen-Lang Lin; Monica Sanchez Contreras; Aleksandra Wojtas; Kelly M Hinkle; Shinsuke Fujioka; Matthew C Baker; Ronald L Walton; Yari Carlomagno; Patricia H Brown; Audrey J Strongosky; Naomi Kouri; Melissa E Murray; Leonard Petrucelli; Keith A Josephs; Rosa Rademakers; Owen A Ross; Zbigniew K Wszolek; Dennis W Dickson Journal: Acta Neuropathol Date: 2015-04-22 Impact factor: 17.088
Authors: P Tacik; M Sanchez-Contreras; M DeTure; M E Murray; R Rademakers; O A Ross; Z K Wszolek; J E Parisi; D S Knopman; R C Petersen; D W Dickson Journal: Neuropathol Appl Neurobiol Date: 2017-03-08 Impact factor: 8.090
Authors: E Iseki; T Matsumura; W Marui; H Hino; T Odawara; N Sugiyama; K Suzuki; H Sawada; T Arai; K Kosaka Journal: Acta Neuropathol Date: 2001-09 Impact factor: 17.088
Authors: I Ferrer; I Hernández; M Boada; A Llorente; M J Rey; A Cardozo; M Ezquerra; B Puig Journal: Acta Neuropathol Date: 2003-08-29 Impact factor: 17.088
Authors: Gabor G Kovacs; Katalin Majtenyi; Salvatore Spina; Jill R Murrell; Ellen Gelpi; Romana Hoftberger; Graham Fraser; R Anthony Crowther; Michel Goedert; Herbert Budka; Bernardino Ghetti Journal: J Neuropathol Exp Neurol Date: 2008-10 Impact factor: 3.685
Authors: Shelley L Forrest; Jillian J Kril; Claire H Stevens; John B Kwok; Marianne Hallupp; Woojin S Kim; Yue Huang; Ciara V McGinley; Hellen Werka; Matthew C Kiernan; Jürgen Götz; Maria Grazia Spillantini; John R Hodges; Lars M Ittner; Glenda M Halliday Journal: Brain Date: 2018-02-01 Impact factor: 13.501
Authors: Juan Francisco Vázquez-Costa; María Payá-Montes; Marina Martínez-Molina; Teresa Jaijo; Jazek Szymanski; Miguel Mazón; Pablo Sopena-Novales; Jordi Pérez-Tur; Teresa Sevilla Journal: Front Mol Neurosci Date: 2021-08-30 Impact factor: 5.639
Authors: Shunsuke Koga; Keith A Josephs; Ikuko Aiba; Mari Yoshida; Dennis W Dickson Journal: J Neurol Neurosurg Psychiatry Date: 2022-06-13 Impact factor: 13.654
Authors: Isidro Ferrer; Pol Andrés-Benito; Maria Victoria Zelaya; Maria Elena Erro Aguirre; Margarita Carmona; Karina Ausín; Mercedes Lachén-Montes; Joaquín Fernández-Irigoyen; Enrique Santamaría; José Antonio Del Rio Journal: Acta Neuropathol Date: 2020-01-06 Impact factor: 17.088